-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Palmitoylethanolamide
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/544-31-0.gif)
| Category | Influenza Virus |
| CAS | 544-31-0 |
| Description | Palmitoylethanolamide is an endogenous cannabinoid found in brain, liver, and other mammalian tissues. It is a weak ligand of the cannabinoid 1 (CB1) and cannabinoid 2 (CB2) receptors, and a selective GPR55 agonist (EC50 values are 4, 19 800 and > 30 000 nM at GPR55, CB2 and CB1 receptors respectively). Nutritional supplement in health care products. |
Product Information
| Synonyms | N-(2-Hydroxyethyl)hexadecanamide; Palmidrol; PEA |
| IUPAC Name | N-(2-hydroxyethyl)hexadecanamide |
| Molecular Weight | 299.5 |
| Molecular Formula | C18H37NO2 |
| Canonical SMILES | CCCCCCCCCCCCCCCC(=O)NCCO |
| InChI | InChI=1S/C18H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-18(21)19-16-17-20/h20H,2-17H2,1H3,(H,19,21) |
| InChIKey | HXYVTAGFYLMHSO-UHFFFAOYSA-N |
| Boiling Point | 461.5±28.0 °C at 760 mmHg |
| Melting Point | 99 °C |
| Flash Point | 232.9°C |
| Purity | ≥98% (HPLC) |
| Density | 0.91 g/cm³ |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | White solid |
| Application | Ingredient of health care products. |
| Storage | Store in a cool and dry place (or refer to the Certificate of Analysis). |
| Complexity | 219 |
| Exact Mass | 299.282429423 |
| Index Of Refraction | 1.463 |
| In Vitro | Palmitoylethanolamide (Palmidrol) itself does not stimulate interferon production in mice treated per os or intravenously. But repeated application of this drug per os induces a macrophage activation, reflected by enhanced interferon production in vitro. When the interferon stimulation is delayed until 4 to 10 days after the first dose of Palmitoylethanolamide, interferon response to ds-RNA is slightly increased. After this phase of enhanced activity a decreased production of interferon is observed. Palmitoylethanolamide is not significantly effective in protecting mice from lethal dose of EMC virus. Application of this drug has an inhibitory effect on the toxicity of ds-RNA. A possible explanation of the mechanism by which Palmitoylethanolamide decreased the toxicity of virus in the organism is discussed. |
| PSA | 49.33 |
| Target | Influenza Virus; Endogenous Metabolite |
| Vapor Pressure | 0.0±2.6 mmHg at 25°C |
| XLogP3-AA | 6.2 |
